Recent Company News

• 04:43 PM ET Aug 07, 2025
  

  Sutro Biopharma reports Q2 EPS ($0.14) vs FactSet ($0.38) [10 est, ($0.64)-(0.04)] ($0.80, 0.00)

• 02:57 AM ET Jul 31, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:14 AM ET Jul 31, 2025
  

  StreetAccount Metrics Recap - Ipsen Q2 Sales (€111.80, 0.00)

• 01:09 AM ET Jul 31, 2025
  

  Ipsen reports H1 Core EPS €6.07 vs FactSet €5.52 [1 est] (€111.80, 0.00)

• 09:37 AM ET Jul 30, 2025
  

  StreetAccount Consensus Metrics Preview - Ipsen Q2 Sales /H1 Earnings (€112.10, -0.30)

• 01:44 PM ET Jul 24, 2025
  

  Cabometyx approved in the EU for previously treated advanced neuroendocrine tumors (€111.10, 0.00)

• 05:14 PM ET Jul 16, 2025
  

  FDA grants orphan drug designation to elafibranor for primary sclerosing cholangitis (PSC) (€105.70, 0.00)

• 10:38 PM ET Jul 12, 2025
  

  Rhythm Pharmaceuticals presents new data on setmelanotide, bivamelagon at ENDO 2025 ($86.70, 0.00)

• 08:13 AM ET Jun 20, 2025
  

  EMA CHMP publishes summary of opinions for June 2025 meeting

• 06:59 AM ET Jun 20, 2025
  

  Exelixis notes Ipsen receipt of positive CHMP opinion for Cabometyx ($40.74, 0.00)